Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France
Author(s)
Frederic MATONTI, MD PhD1, pierre-henry GABRIELLE, MD PhD2, Frank BECQUET, MD PhD3, Margaux AZAR, PharmD4, Henri LESAGE, PharmD5, Jérémy CARETTE, PharmD5, Henri Leleu, PhD, MD5, Roula Ajjouri, MBA4.
1Université Aix Marseille, Aix-en-Provence, France, 2CHU de Dijon, Dijon, France, 3institut ophtalmologique de l'ouest, Nantes, France, 4ROCHE, Boulogne-Billancourt, France, 5Public Health Expertise - Cencora, Paris, France.
1Université Aix Marseille, Aix-en-Provence, France, 2CHU de Dijon, Dijon, France, 3institut ophtalmologique de l'ouest, Nantes, France, 4ROCHE, Boulogne-Billancourt, France, 5Public Health Expertise - Cencora, Paris, France.
OBJECTIVES: Neovascular age-related macular degeneration (nAMD) is a leading cause of visual impairment and blindness in people over 50 years affecting 8% of the French population, with a prevalence increasing with age. It is usually treated with intravitreal (IVT) injections of anti-vascular endothelial growth factors (VEGF). The Port Delivery Plateform (PD-P SUSVIMO), an intraocular implant for continuous delivery of ranibizumab 100 mg/mL with a refill every 6 months, demonstrated non-inferiority versus monthly ranibizumab injections in the ARCHWAY study. The frequent IVT injections represents a significant burden on patients, caregivers and healthcare systems. This study assessed the organizational and economic impact of the PD-P SUSVIMO compared with regular IVT injections in France.
METHODS: To assess the organizational impact, we conducted a literature review and expert interviews to estimate the frequency of injections, the use of medical transport, the time allocated by patients and caregivers for treatment, caregivers’ productivity losses, the occurrence of adverse events, the impact on quality of life and the environmental impact in patients with nAMD treated in France. Associated costs were estimated from the literature and national databases. The analysis compared patients receiving regular IVT injections every 4-8 weeks (target population with the highest persistent medical need) with patients treated with PD-P SUSVIMO. Uncertainty was assessed through scenario and sensitivity analyses.
RESULTS: PD-P SUSVIMO would prevent 5.5 to 6.5 injections per patient per year compared with standard IVT anti-VEGF treatment. It would prevent 25% to 50% medical transports related to injections, and 4 to 5 days for patients and caregivers. This would also save at least 3 hours per caregivers in lost productivity annually. These benefits lead to savings for the French healthcare system.
CONCLUSIONS: By reducing the frequency of IVT injections of anti-VEGF, PD-P SUSVIMO could significantly reduce the burden on nAMD patients, leading to substantial savings.
METHODS: To assess the organizational impact, we conducted a literature review and expert interviews to estimate the frequency of injections, the use of medical transport, the time allocated by patients and caregivers for treatment, caregivers’ productivity losses, the occurrence of adverse events, the impact on quality of life and the environmental impact in patients with nAMD treated in France. Associated costs were estimated from the literature and national databases. The analysis compared patients receiving regular IVT injections every 4-8 weeks (target population with the highest persistent medical need) with patients treated with PD-P SUSVIMO. Uncertainty was assessed through scenario and sensitivity analyses.
RESULTS: PD-P SUSVIMO would prevent 5.5 to 6.5 injections per patient per year compared with standard IVT anti-VEGF treatment. It would prevent 25% to 50% medical transports related to injections, and 4 to 5 days for patients and caregivers. This would also save at least 3 hours per caregivers in lost productivity annually. These benefits lead to savings for the French healthcare system.
CONCLUSIONS: By reducing the frequency of IVT injections of anti-VEGF, PD-P SUSVIMO could significantly reduce the burden on nAMD patients, leading to substantial savings.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE604
Topic
Economic Evaluation, Medical Technologies, Organizational Practices
Topic Subcategory
Budget Impact Analysis
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)